Characterization and product formulation of cholesterol-lowering probiotic strains for prevention of metabolic syndrome
Keywords:
probiotics, Lactobacillus, Bifidobacterium, metabolic syndromeAbstract
Metabolic syndrome (Mets) is influenced by factors such as being overweight, consuming a high calory diet, and little exercise. Obesity, dyslipidemia, hypertension, and hyperglycemia are all part of Mets, which may result in non-communicable diseases. Several researches indicated that moderate consumption of certain probiotic strains could reduce the risk factors of Mets. In this study, three probiotic strains including Lactobacillus paracasei MSMC39-1, Lactobacillus reuteri TF-7 and Bifidobacterium animalis MSMC83 with specific properties in lowering cholesterol, reducing inflammation, and increasing antioxidants, were selected. Cell morphological phenotypes of each probiotic were studied by a scanning electron microscope. The growth characteristics of postbiotics were analyzed and probiotics were cultivated in a 5-liter bioreactor to optimize the best conditions to increase their yield. A combined capsule product was formulated with probiotic ingredients. These products were evaluated for tolerance to simulated gastrointestinal conditions, viability and stability at 4°C and 25°C, and ability to produce bile salt hydrolase (BSH). The results indicated that postbiotics propionic acid and butyric acid were fermented by probiotic metabolites. Probiotic products significantly increased probiotic survival when compared with probiotic-free cells in simulated gastrointestinal conditions. In addition, the viability of probiotics was demonstrated at concentrations greater than 106 CFU/g after storage at 4°C and 25°C for 6 months. Cholesterol-lowering properties of BSH of the probiotics in capsule were maintained during storage. Therefore, the probiotic product can be applied to improve anthropometric and biochemical outcomes in individuals with MetS. However, more research is needed to evaluate the effectiveness of probiotic products in clinical trials
References
Falkner B, Cossrow ND. Prevalence of
metabolic syndrome and obesityassociated hypertension in the racial
ethnic minorities of the United States. Curr
Hypertens Rep 2014;16(7):449.
Song HK, Lim TJ, Lim S, et al. Effect of
probiotics on obesity-related markers per
enterotype: a double-blind, placebocontrolled, randomized clinical trial. EPMA
J 2020;11(1):31-51.
Hill C, Guarner F, Reid G, et al. The
International Scientific Association for
probiotics and prebiotics consensus
statement on the scope and appropriate
use of the term probiotic. Nat Rev
Gastroenterol Hepatol 2014;11(8):506-514.
Senghor, Bruno S, Cheikh R, et al. Gut
microbiota diversity according to dietary
habits and geographical provenance. Hum
Microbiome J 2018;7:1-9.
Sanders ME. Probiotics: definition, sources,
selection, and uses. Clin Infect Dis 2008;
(2):S58-61,S144-151.
Razmpoosh E, Javadi A, Ejtahed HS, et al.
The effect of probiotic supplementation
on glycemic control and lipid profile in
patients with type 2 diabetes: A randomized
placebo-controlled trial. Diabetol Metab
Syndr 2019;13(1):175–182.
Sivamaruthi BS, Kesika P, Suganthy N, et
al. A review on role of microbiome in
obesity and antiobesity properties of
probiotic supplements. Biomed Res Int
: 3291367.
Ashraf R, Shah NP. Immune system
stimulation by probiotic microorganisms.
Crit Rev Food Sci Nutr 2014;54(7):938-956.
Araújo M, Botelho B, Ribeiro D, et al. A
multiple-strain probiotic product provides
a better enzymatic antioxidant response
in individuals with constipation in a
double-blind randomized controlled trial.
Nutr J 2021;89:111225.
Tomaro-Duchesneau C JM, Shah D, et al.
Cholesterol assimilation by Lactobacillus
probiotic bacteria: an in vitro investigation.
Biomed Res Int 2014:380316.
Chand D, Avinash VS, Yadav Y, et al.
Molecular features of bile salt hydrolases
and relevance in human health. Biochim
Biophys Acta Gen Subj 2017;1861(1 Pt
A):2981-91.
Bourebaba Y, Marycz K, Mularczyk M, et
al. Postbiotics as potential new therapeutic
agents for metabolic disorders management.
Biomed Pharmacother 2022;153:113138.
Park M, Joung M, Park JH, et al. Role of
postbiotics in diet-induced metabolic
disorders. Nutr J 2022;14(18):3701.
Neffe-Skociska K, Rzepkowska A,
Szydłowska A, et al. Chapter 3 - Trends
and Possibilities of the use of probiotics
in food production. In: Holban AM,
Grumezescu AM, editors. Alternative and
replacement foods: Academic press; 2018.
p. 65-94.
Terpou A, Papadaki A, Lappa IK,
Kachrimanidou V, Bosnea LA, Kopsahelis
N. Probiotics in food systems: Significance
and emerging strategies towards improved
viability and delivery of enhanced
beneficial value. Nutr J. 2019;11(7):1591.
Naissinger da Silva M, Tagliapietra BL, et al.
In vitro test to evaluate survival in the
gastrointestinal tract of commercial
probiotics. Curr Res Nutr Food Sci. 2021;
:320-325.
Narathip P, Boonyarut L, Anongnard K,
Somboon T, et al. Cholesterol-lowering
activity and functional characterization of
lactic acid bacteria isolated from traditional
Thai foods for their potential used as
probiotic. Songklanakarin J Sci Technol
;43(5):1283-1291
Porntipha V, Praphaiphan K, Fabien L, et al.
Antioxidant activity of Bifidobacterium
animalis MSMC83 and its application in
set-style probiotic yoghurt. Food Biosci
;43:101259.
Porntipha V, Anongnard K, Narathip P, et al.
Bifidobacterium animalis MSMC83
Improves oxidative stress and gut
microbiota in D-Galactose-induced rats.
Antioxidants. 2022; 11(11):2146.
Boonyarut L, Piyatida T, Poolpol P, et al.
Anti-inflammatory effect of probiotic
Lactobacillus paracasei MSMC39-1 on
alcohol-induced hepatitis in rats. J App
Pharm Sci. 2021;11:46-56.
Dalcanton F, Carrasco E, Pérez-Rodríguez
F, et al. Modeling the combined effects
of temperature, pH, and sodium chloride
and sodium lactate concentrations on the
growth rate of Lactobacillus plantarum
ATCC 8014. J. Food Qual. 2018;2018:1726761.
liewska K, Chlebicz-Wójcik A. Growth
kinetics of probiotic Lactobacillus strains
in the alternative, cost-efficient semi-solid
fermentation medium. Biology (Basel)
;9(12):423.
NP Shah. Bacteria, beneficialBifidobacterium
spp.: Morphology and Physiology. Encyclopedia
of Dairy Sciences. 2nd ed. 2011. p.381-7.
Salminen S, Collado MC, Endo A, et al.
The International Scientific Association of
Probiotics and Prebiotics (ISAPP) consensus
statement on the definition and scope of
postbiotics. Nat Rev Gastroenterol Hepatol
;18(9):649-67.
Wegh CAM, Geerlings SY, Knol J, et al.
Postbiotics and their potential applications
in early life nutrition and beyond. Int J Mol
Sci 2019;20(19):4673.
He J, Zhang P, Shen L, et al. Short-chain
fatty acids and their association with
signalling pathways in inflammation,
glucose and lipid metabolism. Int J Mol
Sci 2020;21(17):6356.
Heimann E, Nyman M, Degerman E.
Propionic acid and butyric acid inhibit
lipolysis and de novo lipogenesis and
increase insulin-stimulated glucose uptake
in primary rat adipocytes. Adipocyte
;4(2):81-88.
Arora T, Tremaroli V. Therapeutic potential
of butyrate for treatment of type 2 diabetes.
Front Endocrinol 2021;12:761834.
Wu H, Tremaroli V, Schmidt C, et al. The
gut microbiota in prediabetes and diabetes:
a population-based cross-sectional study.
Cell Metab 2020;32:379–90.e3
Leng RA, Steel JW, Luick JR. Contribution
of propionate to glucose synthesis in
sheep. Biochem J 1967;103:785–90.
Adachi K, Sugiyama T, Yamaguchi Y, et al.
Gut microbiota disorders cause type 2
diabetes mellitus and homeostatic
disturbances in gut-related metabolism in
japanese subjects. J Clin Biochem Nutr
;64:231–8.
Sensoy I. A review on the food digestion
in the digestive tract and the used in vitro
models. Curr Res Food Sci 2021;4:308-319.
Ticho AL, Malhotra P, Dudeja PK, et al.
Intestinal absorption of bile acids in health
and disease. Compr Physiol 2019;10(1):21-56.
Al-Tabakha MM. HPMC capsules: current
status and future prospects. J Pharm
Pharm Sci. 2010;13(3):428-42.
Kimoto H, Ohmomo S, Okamoto T.
Cholesterol removal from media by
lactococci. J Dairy Sci 2002;85(12):3182-8.
Lye H-S, Rahmat-Ali GR, Liong M-T.
Mechanisms of cholesterol removal by
lactobacilli under conditions that mimic
the human gastrointestinal tract. Intl Dairy
J 2010;20(3):169-75.
Costabile A, Buttarazzi I, Kolida S, et al. An
in vivo assessment of the cholesterollowering efficacy of Lactobacillus
plantarum ECGC 13110402 in normal to
mildly hypercholesterolaemic adults.
PLoS One 2017;12(12):e0187964.
Chand D, Avinash VS, Yadav Y, et al.
Molecular features of bile salt hydrolases
and relevance in human health. Biochim
Biophys Acta Gen Subj 2017;1861(1 Pt A):
-91.
Tsai CC, Lin PP, Hsieh YM, et al. Cholesterollowering potentials of lactic acid bacteria
based on bile-salt hydrolase activity and
effect of potent strains on cholesterol
metabolism in vitro and in vivo. Sci World
J 2014;2014:690752.
Kumar M, Nagpal R, Kumar R, et al.
Cholesterol-lowering probiotics as
potential biotherapeutics for metabolic
diseases. Exp Diabetes Res 2012;2012:
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
